Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Daiichi Sankyo
Argus Health
Healthtrust
UBS
Queensland Health
Medtronic
Boehringer Ingelheim
Harvard Business School

Generated: April 26, 2018

DrugPatentWatch Database Preview

JEVTANA KIT Drug Profile

« Back to Dashboard

Which patents cover Jevtana Kit, and what generic alternatives are available?

Jevtana Kit is a drug marketed by Sanofi Aventis Us and is included in one NDA. There are three patents protecting this drug.

This drug has two hundred and five patent family members in fifty-eight countries.

The generic ingredient in JEVTANA KIT is cabazitaxel. There are thirteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cabazitaxel profile page.
Summary for JEVTANA KIT
Drug patent expirations by year for JEVTANA KIT
Synonyms for JEVTANA KIT
(((tertbutoxy)carbonyl)amino)-2-hydroxy-3-phenylpropanoate1-hydroxy-7beta,10beta-dimethoxy-9-oxo-5beta,20-epoxytax-11-ene-2alpha,4,13alpha-triyl 4-acetate 2-benzoate 13-((2R,3S)-3-
(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1-hydroxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0;{3,10}.0;{4,7}]hept
(1S)-5beta,20-Epoxy-9-oxo-7beta,10beta-dimethoxytaxa-11-ene-1,2alpha,4alpha,13alpha-tetraol 2-benzoate 4-acetate 13-[(2R,3S)-2-hydroxy-3-(tert-butoxycarbonylamino)-3-phenylpropionate]
(2alpha,5beta,7beta,10beta,13alpha)-4-acetoxy-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-acetoxy-9-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-acetoxy-9-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1
1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-ene-2,4,13-triyl 4-acetate 2-benzoate 13-((2R,3S)-3-(((tertbutoxy)carbonyl)amino)-2-hydroxy-3-phenylpropanoate)
183133-96-2
51F690397J
890654-44-1
A25044
AB01273971_02
AB01273971-01
ABP001072
AKOS032947285
AN-1492
BC252842
BMQGVNUXMIRLCK-OAGWZNDDSA-N
C45H57NO14
CABAZITAXEL
Cabazitaxel (Jevtana)
Cabazitaxel (USAN/INN)
Cabazitaxel [USAN:INN]
cabazitaxel acetonate
Cabazitaxel Injection
Cabazitaxel; TXD-258
Cabazitaxelum
CHEBI:63584
CHEMBL1201748
CS-0972
D02HSB
D09755
DB06772
DTXSID40171389
EX-A838
GTPL6798
HY-15459
J-011721
J-519981
javtana
Jevanta
Jevtana
Jevtana (TN)
MFCD18827611
MolPort-023-299-439
NCGC00346704-01
NSC-761432
NSC761432
RPR 116258A
RPR-116258A
s3022
SC-94928
SCHEMBL179674
SR-01000941585
SR-01000941585-1
Taxoid XRP6258
TXD 258
TXD258
UNII-51F690397J
W-5799
X7252
XRP 6258
XRP-6258
Xrp6258
ZINC85536932

US Patents and Regulatory Information for JEVTANA KIT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;IV (INFUSION) 201023-001 Jun 17, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;IV (INFUSION) 201023-001 Jun 17, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;IV (INFUSION) 201023-001 Jun 17, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;IV (INFUSION) 201023-001 Jun 17, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for JEVTANA KIT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;IV (INFUSION) 201023-001 Jun 17, 2010 ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;IV (INFUSION) 201023-001 Jun 17, 2010 ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;IV (INFUSION) 201023-001 Jun 17, 2010 ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;IV (INFUSION) 201023-001 Jun 17, 2010 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for JEVTANA KIT

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,593,482 Methods for preparing new taxoids and pharmaceutical compositions containing them ➤ Sign Up
6,372,780 Methods of treating cell lines expressing multidrug resistance P-glycoprotein ➤ Sign Up
6,187,916 Process for the preparation of taxane derivatives and .beta.-lactam intermediates therefor ➤ Sign Up
6,218,553 Process for the preparation of taxane derivatives and .beta.-lactam intermediates therefor ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for JEVTANA KIT

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/2013 Austria ➤ Sign Up PRODUCT NAME: DIMETHOXYDOCETAXEL-ACETONSOLVAT (CABAZITAXEL-ACETONSOLVAT); REGISTRATION NO/DATE: EU/1/11/676/001 20110317
00595 Netherlands ➤ Sign Up PRODUCT NAME: CABAZITAXEL ACETONAAT; REGISTRATION NO/DATE: EU/1/11/676/001 20110317
2013010 Lithuania ➤ Sign Up PRODUCT NAME: CABAZITAXELUM; REGISTRATION NO/DATE: EU/1/11/676/001 20110317
1 5019-2013 Slovakia ➤ Sign Up FIRST REGISTRATION NO/DATE: EU/1/11/676/001 20110317
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Express Scripts
McKesson
Queensland Health
Mallinckrodt
Chubb
Citi
Medtronic
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.